A  Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis

A  Phase IV Study of the Safety and Efficacy of CinnoPar® in Iranian Patients with Osteoporosis

The safety of teriparatide has been studied in various phase III and phase IV trials. However, a postmarketing study of the biosimilar of teriparatide, CinnoPar®, has not been conducted on Iranian patients. This was a phase IV study conducted on osteoporotic patients who received an Iranian teripara...

Full description

Bibliographic Details
Main Authors: Ahmadreza Jamshidi, Farhad Gharibdoost, Sima Sedighi, Asghar Hajiabbasi, Amir-Hossein Salari, Alireza Khabbazi, Peyman Mottaghi, Ahmad Tahammoli Roudsari, Mehrdad Aghaei, Irandokht Shenavar Masooleh, Araz Sabzvari, Nassim Anjidani
Format: Article
Language:English
Published: Hindawi Limited 2021-01-01
Series:Journal of Osteoporosis
Online Access:http://dx.doi.org/10.1155/2021/7584308

Internet

http://dx.doi.org/10.1155/2021/7584308

Similar Items